PDX Portal

Model Details

Patient Information for Model: BCM-15100

Model Contact

Model: BCM-15100
Model Contact: Michael Lewis
Institution: BCM Breast PDX Program
Email: mtlewis@bcm.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: BCM-15100

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

GeneFilter by Gene	ChrFilter by Chr	Start	End	Ref	Alt	cDNA Change	Codon Change	Protein Change	TVAF	Gene Mutation Freq.	Site Mutation Freq.	Most Severe Effect	All Effects	Mutation Impact	Transcript ID	ClinVar Clinical Significance	COSMIC ID	gnomAD Non-Cancer AF	dbSNP ID	Gene Mutation Freq.	Site Mutation Freq.	Transcript ID	ClinVar Clinical Significance	COSMIC ID	dbSNP ID
AKAP9	chr7	92022864	92022864	A	AAAC	c.4004_4006dup	aaa/aAACaa	p.K1335_L1336insQ	0.963	50	35	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000356239.8		COSV62337888		rs10644111	50	35	ENST00000356239.8		COSV62337888	rs10644111
ARID1B	chr6	156778268	156778268	C	CCAGCAG	c.606_611dup	-/CAGCAG	p.Q213_Q214dup	0.914	37	3	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000636930.2		COSV51647062			37	3	ENST00000636930.2		COSV51647062
ATRX	chrX	77682471	77682471	C	G	c.2785G>C	Gag/Cag	p.E929Q	0.985	59	56	Missense Variant	Missense Variant	MODERATE	ENST00000373344.10	Benign			rs3088074	59	56	ENST00000373344.10	Benign		rs3088074
CHD4	chr12	6599898	6599898	G	A	c.1357C>T	Cgg/Tgg	p.R453W	0.441	5	1	Missense Variant	Missense Variant	MODERATE	ENST00000544040.7				rs1948560535	5	1	ENST00000544040.7			rs1948560535
CIITA	chr16	10909070	10909070	A	G	c.2702A>G	cAg/cGg	p.Q901R	0.977	85	84	Missense Variant	Missense Variant	MODERATE	ENST00000618327.4	Benign		0.983235000000	rs7197779	85	84	ENST00000618327.4	Benign		rs7197779
CLIP1	chr12	122279123	122279123	C	A	c.3670G>T	Gca/Tca	p.A1224S	0.7	4	2	Missense Variant	Missense Variant	MODERATE	ENST00000620786.4	Likely_benign		0.005091810000	rs17881033	4	2	ENST00000620786.4	Likely_benign		rs17881033
COL1A1	chr17	50197978	50197978	G	C	c.613C>G	Cct/Gct	p.P205A	0.634	11	2	Missense Variant	Missense Variant	MODERATE	ENST00000225964.10	Conflicting_interpretations_of_pathogenicity		0.003288860000	rs72667032	11	2	ENST00000225964.10	Conflicting_interpretations_of_pathogenicity		rs72667032
CREB3L2	chr7	137928167	137928170	CTGG	C	c.299_301del	aCCAgt/agt	p.T100del	0.534	49	49	In-frame Deletion	In-frame Deletion	MODERATE	ENST00000330387.11		COSV57791862		rs3217268	49	49	ENST00000330387.11		COSV57791862	rs3217268
CREBBP	chr16	3729114	3729114	T	C	c.5933A>G	aAc/aGc	p.N1978S	0.348	7	1	Missense Variant	Missense Variant	MODERATE	ENST00000262367.10	Benign	COSV52116951	0.005018440000	rs112906840	7	1	ENST00000262367.10	Benign	COSV52116951	rs112906840
CYSLTR2	chr13	48706965	48706965	T	G	c.148T>G	Ttc/Gtc	p.F50V	0.489	7	1	Missense Variant	Missense Variant	MODERATE	ENST00000282018.4	Likely_benign		0.004790270000	rs143085034	7	1	ENST00000282018.4	Likely_benign		rs143085034
CYSLTR2	chr13	48707649	48707649	T	A	c.832T>A	Tta/Ata	p.L278I	0.466	7	1	Missense Variant	Missense Variant	MODERATE	ENST00000282018.4	Likely_benign		0.004793390000	rs138722135	7	1	ENST00000282018.4	Likely_benign		rs138722135
CYSLTR2	chr13	48707125	48707125	A	G	c.308A>G	aAt/aGt	p.N103S	0.431	7	1	Missense Variant	Missense Variant	MODERATE	ENST00000282018.4	Likely_benign		0.005091080000	rs116932219	7	1	ENST00000282018.4	Likely_benign		rs116932219
EP300	chr22	41117525	41117525	C	T	c.433C>T	Cag/Tag	p.Q145*	0.417	22	1	Nonsense Mutation	Nonsense Mutation	HIGH	ENST00000263253.9		COSV54331679			22	1	ENST00000263253.9		COSV54331679
ERCC2	chr19	45351661	45351661	T	G	c.2251A>C	Aag/Cag	p.K751Q	0.954	48	46	Missense Variant	Missense Variant	MODERATE	ENST00000391945.10	Benign/Likely_benign	COSV67266431	0.322955000000	rs13181	48	46	ENST00000391945.10	Benign/Likely_benign	COSV67266431	rs13181
ESR1	chr6	152098788	152098788	A	C	c.1610A>C	tAt/tCt	p.Y537S	0.97	10	3	Missense Variant	Missense Variant	MODERATE	ENST00000440973.5		COSV52783938			10	3	ENST00000440973.5		COSV52783938

CNV

PDX Validation

In order to validate the identity of Baylor College of Medicine patient-derived xenograft (PDX) models, short tandem repeat (STR) testing is performed at the Cytogenetics and Cell Authentication core facility at MDACC. STR testing is performed on tissue from the initial tumor grown in the mouse (transplant generation 1 - TG1) and from a patient sample when possible. Thereafter, STR testing is performed every five transplant generations (TG5, TG10, TG15, and TG20). In the case that a PDX model is transplanted from viably frozen tissue to restart the model, the PDX Core will test the first outgrowth to confirm identity and every five transplant generations thereafter. In addition to STR, we assess clinical biomarkers and histology every 5th transplant generation. Finally, RNAseq gene expression profiles are evaluated periodically to ensure consistency with previous results and to evaluate phenotypic drift. If a significant change in PDX biology is noted, we identify the last known stable stock and re-start the model.

Histology Information for Model: BCM-15100

There are no histology images for this model.

Metastasis Information for Model: BCM-15100

Patient

PDX

Abdomen

Adrenal gland

Bone

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

Liver

Lung

Lymph node

Lymph nodes

Neck

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

Patient Treatment Information for Model: BCM-15100

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Pathologic Response	Reason Stopped
15	Cyclophosphamide,Docetaxel	Adjuvant	38.08	38.34	95 days	Not Reported	Not Applicable	Treatment Completed
20	Radiation Therapy	Adjuvant	38.34	38.42	29 days	Not Reported	Not Applicable	Treatment Completed
25	Tamoxifen	Adjuvant	38.5	39.64	416 days	Progressive Disease	Not Applicable	Disease Progression
35	Leuprolide,Denosumab	Metastatic	39.64	39.72	29 days	Disease Progression	Not Applicable	Disease Progression
40	Oophorectomy	Prophylactic	39.7	39.7	1	Not Reported	Not Applicable	Other
45	Letrozole,Denosumab	Metastatic	39.72	42.09	865 days	Not Reported	Not Applicable	Side Effects
55	Tamoxifen	Metastatic	42.09	42.1	4 days	Disease Progression	Not Applicable	Disease Progression
65	Denosumab,Paclitaxel	Metastatic	42.14	42.38	88 days	Not Reported	Not Applicable	Unknown
70	Fulvestrant,Denosumab	Metastatic	42.4	43.26	314 days	Disease Progression	Not Applicable	Disease Progression
85	Capecitabine,Denosumab	Metastatic	43.27	44.0	266 days	Disease Progression	Not Applicable	Disease Progression
100	Fulvestrant,Palbociclib	Metastatic	44.09	44.63	197 days	Disease Progression	Not Applicable	Disease Progression
120	Doxorubicin	Metastatic	44.74	45.34	219 days	Disease Progression	Not Applicable	Disease Progression
130	Eribulin	Metastatic	45.45	45.67	80 days	Disease Progression	Not Applicable	Disease Progression
150	Carboplatin	Metastatic	45.67	45.7	11 days	Not Reported	Not Applicable	Side Effects
155	Stereotactic radiosurgery	Metastatic	45.78	45.78	1	Not Reported	Not Applicable	Unknown